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Background: To treat acute schizophrenia, a long-acting injectable antipsychotic needs a rapid onset of action and
therapeutic profile similar to that of oral agents. The present post-hoc analyses compared results from a
randomized, double-blind, placebo-controlled trial of olanzapine long-acting injection (LAI) for acute schizophrenia
with those observed in similarly designed trials of oral olanzapine.
Methods: Six-week results from the olanzapine LAI study (N = 404) were compared with those of 3 oral studies
(study 1: olanzapine vs. haloperidol vs. placebo [N= 335]; study 2: olanzapine vs. haloperidol vs. low-dose
olanzapine [N = 431]; study 3: olanzapine vs. placebo vs. low-dose olanzapine [N = 152]). All patients had baseline
Brief Psychiatric Rating Scale (BPRS) scores ≥24 (0–6 scale). Six-week effect sizes were calculated. Efficacy onset,
pharmacokinetics, discontinuations, weight gain, and extrapyramidal symptoms were also assessed.
Results: At 6 weeks, mean BPRS scores decreased by 14 to 15 points for olanzapine LAI (405 mg/4 weeks, 210 or
300 mg/2 weeks), by 8 to 16 for oral olanzapine (10 ± 2.5 or 15 ± 2.5 mg/day), and by 12 to 13 for haloperidol
(15 ± 5 mg/day). For those same dose groups, effect sizes vs. placebo for the BPRS were 0.7 to 0.8 for olanzapine
LAI, 0.5 to 0.7 for oral olanzapine, and 0.6 for haloperidol. The first statistically significant separation from placebo on
the BPRS occurred at 3 days for the olanzapine LAI groups and at 1 week for oral olanzapine and haloperidol
(15 ± 5 mg/day) in oral study 1 although as late as week 6 for the 10-mg/day olanzapine dose in oral study 3.
Olanzapine concentrations were similar across studies. Weight gain ≥7% of baseline occurred in up to 35% of
olanzapine LAI and oral patients versus up to 12% of haloperidol and placebo patients. Extrapyramidal symptoms
were lowest in the olanzapine LAI groups and significantly greater in the haloperidol groups. No post-injection
delirium/sedation syndrome events occurred in the olanzapine LAI study.
Conclusions: Patients treated acutely with olanzapine LAI showed a similar pattern of improvement to that seen
historically with oral olanzapine. With the exception of injection-related adverse events, the efficacy and tolerability
profile of olanzapine LAI is similar to oral olanzapine.
Trial registration: ClinicalTrials.gov ID; URL: http//www.clinicaltrials.gov/: NCT00088478; ClinicalStudyResults.org ID;
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In the treatment of patients with acute symptoms of
schizophrenia, second generation oral antipsychotics have
been the treatment of choice, and one of the standards of
care is oral olanzapine [1]. In the United States, the use of
long-acting formulations have been reserved for patients
who have difficulty complying with oral regimens during
maintenance treatment [2-4], and little information is
available about their use for patients with acute symptoms
of schizophrenia [5]. Given the high frequency of insuffi-
cient medication adherence among patients with schizo-
phrenia [6-8], it could be clinically advantageous to be
able to initiate a long-acting depot antipsychotic during an
acute exacerbation. To benefit patients with acute symp-
toms, a long-acting antipsychotic formulation needs a
rapid onset of action, combined with a therapeutic profile
similar to that of second generation oral agents.
Olanzapine long-acting injection (LAI) has demonstrated
efficacy in acutely ill patients [9] and has demonstrated
similarity to oral olanzapine in terms of maintenance of ef-
fect and safety during longer-term treatment [10]; several
recent reviews are available [11-13]. However, no direct
comparisons of oral and LAI olanzapine have been done
within the acute phase of treatment. In order to address
this question, a post-hoc analysis of effect sizes was con-
ducted to compare efficacy results from the acute trial of
olanzapine LAI [9] with historical data from 3 similarly
designed trials of oral olanzapine for the acute treatment of
schizophrenia [14-16]. The 3 oral studies were randomized,
controlled trials using either placebo [14,16] or a non-
therapeutic dose of oral olanzapine (1 mg/day) as the refer-
ence group [15,16]. In addition, oral haloperidol was used
as an active comparator in 2 of these oral olanzapine trials
[14,15], thus potentially allowing for further clinical context
for the olanzapine LAI findings. As in the acute olanzapine
LAI trial, the oral trials required patients to be acutely
symptomatic, and mean Brief Psychiatric Rating Scale
(BPRS) scores (0–6 scale) were similar across all 4 studies,
in the range of 37 to 43, indicating markedly ill patient
populations. While not providing the degree of control pos-
sible in a direct head-to-head comparison, the use of effect
sizes allows for useful comparisons of efficacy data across
trials that employ similar designs and patient populations.
In addition to evaluating effect sizes, we examined onset of
efficacy, defined as the time of first statistical separation
from placebo or a non-therapeutic dose of olanzapine. Fi-
nally, we also provide indirect comparison of key tolerabil-
ity measures across these trials.
Methods
Study criteria
To be included in the analyses, studies had to be rando-
mized, double-blind, fixed- or semi-fixed-dose, placebo-
controlled and/or employing a low non-therapeuticreference dose as control group, at least 6 weeks in
length, and conducted in acutely ill patients with schizo-
phrenia. All were also previously submitted to the Uni-
ted States Food and Drug Administration as part of the
submission for approval for the treatment of schizophre-
nia. The 4 studies meeting these criteria were olanzapine
LAI study F1D-MC-HGJZ [9], oral study F1D-MC-
HGAD [14], oral study F1D-EW-E003 [15], and oral
study F1D-MC-HGAP [16] (See Table 1). All patients
were diagnosed with schizophrenia using then-current
Diagnostic and Statistical Manual of Mental Disorders
(DSM) criteria and had to meet minimum BPRS criteria
(at least ≥24) to ensure that patients were acutely ill at
study entry. Three of the studies compared the respect-
ive formulation of olanzapine (LAI or oral) with placebo
[9,14,16]; two of the studies employed a non-therapeutic
reference dose of oral olanzapine (1 mg/day) [15,16]. In
all 4 studies, patients were required to be inpatients for
at least the first 2 weeks of the study and could poten-
tially become outpatients thereafter if clinically appropri-
ate. The olanzapine LAI study excluded patients who
were known to be treatment-resistant to olanzapine but
did not exclude other treatment-resistant patients. Oral
studies 1 and 2 excluded patients who were known to be
clear non-responders to neuroleptic treatment. Oral
study 3 excluded patients who had failed to show min-
imal clinical response to sufficient doses of at least 3 dif-
ferent neuroleptics from 3 different chemical classes or
to a dose of 400 mg/d of clozapine for at least 6 weeks.
The BPRS total scores and/or the Positive and Nega-
tive Syndrome Scale (PANSS) total scores were used to
assess efficacy. Pharmacokinetic sampling was conducted
in all patients at the end of the visit, just prior to the
next dose for oral patients or just prior to the next injec-
tion for LAI patients when at an injection visit. LAI
patients also had assessments taken periodically between
injections. Heparinized plasma samples were analyzed
for olanzapine using a validated high-performance liquid
chromatography method at the same centralized labora-
tory across all 4 studies. For the LAI study, samples col-
lected >1 day before or after the intended visit interval
were excluded from analysis. Safety measures included
mean change in weight from baseline to endpoint and
the incidence of treatment-emergent weight gain ≥7%
from baseline. Treatment-emergent Parkinsonism was
defined as a Simpson-Angus [17] total baseline score ≤3
and a post-baseline score >3 at anytime. Treatment-
emergent akathisia was defined as a Barnes Akathisia
Rating Scale [18] baseline global score <2 and a post-
baseline score ≥2 at anytime. Patients were allowed to
take benzodiazapines for insomnia, anxiety, or agitation
(≤2 mg/day lorazepam equivalents in the olanzapine LAI
study, and ≤10 mg/day in the 3 oral studies). Anticholin-
ergic use for extrapyramidal symptoms was permitted
Table 1 A summary of the olanzapine long-acting injection and oral olanzapine studies analyzed
Study Dates Conducted Primary Objective Design Treatments, Doses,
and Regimen
N Diagnosis and Inclusion
Criteria




2 – 7 day washout OLZ LAI 404 DSM-IV schizophrenia
8 weeks 405 mg/4 weeks BPRS score ≥30 (0 – 6 scale)
Randomized, 210 mg/2 weeks
double-blind 300 mg/2 weeks
IM placebo/2 weeks




Efficacy vs. placebo and
HAL (BPRS)
4 – 7 day placebo
lead-in
OLZ 335 DSM-III-R schizophrenia with
acute exacerbation
5 ± 2.5 mg/day
6 weeks 10 ± 2.5 mg/day BPRS score ≥24 (0 – 6 scale)
Randomized, 15 ± 2.5 mg/day
double-blind HAL: 15 ± 5 mg/day
Placebo




Efficacy vs. HAL (BPRS) 4 – 7 day placebo
lead-in
OLZ 431 DSM-III-R schizophrenia
with acute exacerbation
5 ± 2.5 mg/day
6 weeks 10 ± 2.5 mg/day BPRS score ≥24 (0 – 6 scale)
Randomized, 15 ± 2.5 mg/day CGI-S score ≥4
double-blind 1 mg/day
HAL: 15 ± 5 mg/day




Efficacy vs. Placebo (BPRS) 4 – 9 day placebo
lead-in
OLZ 152 DSM-III-R schizophrenia with
acute exacerbation
1 mg/day




Abbreviations: BPRS: Brief Psychiatric Rating Scale; CGI-S: Clinical Global Impressions – Severity; DSM: Diagnostic and Statistical Manual (versions III-R: revised; and
IV); OLZ: olanzapine; HAL: haloperidol; OLZ LAI: olanzapine long-acting injection; PANSS: Positive and Negative Syndrome Scale
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prophylatic use was prohibited. No oral antipsychotic
supplementation was allowed in the olanzapine LAI
study. All 4 studies were conducted in accordance with
the ethical principles of the Declaration of Helsinki. Pro-
tocols were conducted consistent with good clinical
practices and all applicable laws and regulations in each
region. Ethical Review Boards approved each protocol
before investigators initiated the trials. All patients or
their legal representative signed an informed consent be-
fore participation in the trial. Detailed information about
each study has been published elsewhere [9,14-16].
Statistical analyses
The data in each of the 4 studies were analyzed on an
intent-to-treat basis, and analysis results from each study
are presented separately here. Standard baseline charac-
teristics were summarized for all randomized patients.
Mean changes from baseline to endpoint were analyzed
using the last-observation-carried-forward approach.Differences between groups in continuous data within
each study were assessed using analysis of variance, with
treatment, investigator (or country), and/or treatment-
by-investigator (or treatment-by-country) interaction as
fixed factors. Differences between groups in categorical
data were assessed with Fisher’s exact test or Pearson’s
chi-square test. All comparisons were conducted at a
two-sided alpha level of 0.05 without adjustment for
multiplicity. Onset of efficacy was defined as the first
time point at which a treatment group achieved statis-
tical superiority to the reference group (placebo or low
non-therapeutic dose) followed by statistical superiority
at all subsequent visits.
Effect size for each treatment group was calculated
against placebo or the non-therapeutic dose of oral olan-
zapine (1 mg/day) as the reference group. Effect size was
calculated as the difference of mean changes in efficacy
measures (BPRS and PANSS total scores) of the treat-
ment group and the reference group (placebo or oral
olanzapine 1 mg/day), divided by their pooled standard
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6 weeks in length while the olanzapine LAI study was
8 weeks in length, only the first 6 weeks of data from
the olanzapine LAI study were used for the between-
study efficacy comparison; however, pharmacokinetic
and safety comparisons were not adjusted for time in
treatment.Results
Baseline symptom severity
Patient demographics and baseline symptom severity
were similar across the 4 studies (Table 2). Patients were
mostly male (64–88%) and Caucasian (56–86%), with
mean ages of 36 to 41 years.Efficacy assessments
Weekly reduction in symptoms assessed by the BPRS in
each of the 4 studies over 6 weeks are shown in Figure 1.
Three of the 4 studies also evaluated symptom changes
with the PANSS (olanzapine LAI study, oral study 2, and
oral study 3), and those results are shown in Additional
file 1: Figure S1.Effect size
Table 3 shows the effect sizes for the BPRS and PANSS
total assessments for each active treatment group in all
4 studies. Most importantly, the placebo-controlled ef-
fect sizes for treatment with olanzapine LAI were com-
parable to the effect sizes for treatment with oral
olanzapine seen in each of the 3 studies. Effect sizes in
oral olanzapine study 2 were lower, but this is due to the
fact that the 1-mg/day oral olanzapine treatment group














Male, n (%) 285 (70.5) 294 (87.8) 275 (63.8) 110 (72.4)
Caucasian, n (%) 226 (55.9) 230 (68.7) 372 (86.3) 104 (68.4)
Mean Age, years (SD) 40.8 (11.2) 36.0 (9.4) 35.5 (10.7) 37.6 (9.2)
Mean Age of Disease
Onset, years (SD)
23.4 (8.2) 22.0 (5.8) 24.1 (7.7) 21.7 (5.7)
Median Length of
Current Episode, days
39 30 32 40
Mean PANSS Total
Score (SD)
101.0 (15.6) – 103.3 (18.4) 98.2 (17.7)
Mean BPRS Total (SD) 40.9 (8.9) 41.5 (11.0) 40.7 (10.6) 38.0 (9.0)
Abbreviations: BPRS: Brief Psychiatric Rating Scale; OLZ LAI: olanzapine long-
acting injection; PANSS: Positive and Negative Syndrome Scale; SD: standard
deviationOnset of efficacy
Onset of efficacy was demonstrated by all 3 doses of olan-
zapine LAI vs. placebo starting at day 3 (p< .05) on the
BPRS. On the PANSS, improvement vs. placebo began at
day 3 for two of the olanzapine LAI dose groups (405 mg/
4 weeks and 300 mg/2 weeks; p< .05) and at week 1 for
the other dose group (210 mg/2 weeks; p< .01). In oral
study 1, the medium and high olanzapine dose groups
(10±2.5 and 15±2.5 mg/day) and the haloperidol group
(15±5 mg/day) all demonstrated onset of efficacy com-
pared with placebo starting at week 1 (p< .05) on the
BPRS; the low dose olanzapine group (5±2.5 mg/day) sepa-
rated from placebo only at week 2 of treatment (p< .05). In
oral study 2, although a similar pattern of symptom reduc-
tion was seen in the active groups, no groups separated sta-
tistically from the very low reference dose comparator
(1 mg/day olanzapine) at any time. In oral study 3, onset of
efficacy for the 10-mg/day olanzapine group began at the
6-week endpoint vs. placebo on the BPRS (p< .05) but
began starting at week 2 on the PANSS (p< .05).
Olanzapine plasma concentrations
The expected therapeutic range for olanzapine plasma
concentrations for within-label doses of olanzapine (oral
or LAI) has been reported as approximately 5 to 73 ng/
mL, representing the 10th percentile for the lowest within-
label dose and the 90th percentile for the highest within
label dose [20]. In the LAI study, mean concentrations
(ng/mL) were in the therapeutic range as early as day 3,
with means of 9.1 (SD=8.6), 17.2 (SD=14.7), and 15.6
(SD=13.3) for the 210-mg/2 week, 405-mg/4 week, and
300-mg/2 week groups, respectively. Table 4 presents
olanzapine plasma concentrations across all studies at
study endpoint. Although study endpoint for the olanza-
pine LAI study was at 8 weeks (vs. 6 weeks for the oral
studies), endpoint results represent the best comparison
as these indicate trough levels for each of the formulations
and dosage regimens, including the 4-week LAI dosage
which would otherwise not be at trough level at 6 weeks.
Weight gain
The safety results from the olanzapine LAI study show
similar patterns of weight gain for patients in the 3 olanza-
pine LAI treatment groups as that reported for the thera-
peutic treatment groups in oral olanzapine studies 1, 2, and
3. At study endpoint, mean weight increased by 2.8–3.9 kg
for olanzapine LAI (p≤ .001 vs. placebo for all LAI doses),
1.7–3.6 kg for oral olanzapine (study 1: p< .05 vs. placebo
for all oral olanzapine doses and p< .05 vs. haloperidol for
the medium and high olanzapine doses; study 2: p< .001
vs. 1 mg oral and p< .01 vs. haloperidol for the medium
and high olanzapine doses; study 3: p< .05 vs. 1 mg and
placebo), and −0.4–0.9 kg for haloperidol (not significant
vs. placebo or 1 mg/day olanzapine). Weight gain ≥7% of
Olanzapine LAI Oral Study 1 
Oral Study 3 
Weeks




















OLZ 1 mg (n=51)
OLZ 10 mg (n=49)
Placebo (n=49)
Weeks





















OLZ 5 mg (n=64)
OLZ 10 mg (n=62)
OLZ 15 mg (n=65)
HAL (n=68)
Weeks




















300 mg Q2W (n=98)
405 mg Q4W (n=100)
210 mg Q2W (n=106)
Placebo (n=98)
Oral Study 2 
Weeks




















OLZ 1 mg (n=83)
OLZ 5 mg (n=85)
OLZ 10 mg (n=83)
OLZ 15 mg (n=85)
HAL (n=79)
Figure 1 Mean changes in BPRS scores during six weeks of treatment in olanzapine long-acting injection and oral olanzapine studies
of acute schizophrenia. In the LAI study, all 3 olanzapine LAI treatment groups showed statistically greater reductions vs. placebo by day 3
(p= .05) and for the remainder of the study. In oral olanzapine study 1, the 10- and 15-mg/day olanzapine groups and the haloperidol group
showed statistically greater reductions vs. placebo at week 1 and beyond (p= .05). In oral study 2, no groups separated statistically from the 1-mg
reference dose although the overall pattern of symptom reductions appeared similar to those in the other studies. In oral olanzapine study 3, the
10-mg/day treatment group showed a significant difference vs. placebo at week 6 (p= .04).
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pine groups, but comparable between the studies for
olanzapine-treated patients: olanzapine LAI vs. placebo
(24%–35% vs. 12%, p’s< .05); study 1 oral olanzapine
(28%–34%) vs. placebo (3%, p’s< .001) and haloperidol
(12%, p< .05); study 2 oral olanzapine (19%–35%) vs. 1 mg
oral (13%, p’s< .05) and haloperidol (4%, p< .05); and
study 3 oral olanzapine (20%) vs. 1 mg oral (6%, p< .05)
and placebo (2%, p< .01).
Extrapyramidal symptoms
Overall incidence of treatment-emergent extrapyramidal
symptoms was lower across all groups in the LAI study
than in the older oral studies, including patients in the
placebo and non-therapeutic control groups, but wasmarkedly lower for the LAI and oral olanzapine groups
than the haloperidol groups. Incidence of Parkinsonism in
the olanzapine LAI study showed no statistically significant
difference between drug and placebo (2%–6% olanzapine
LAI vs. 6% placebo), nor was there a significant difference
between therapeutic oral olanzapine doses and placebo
(study 1: 12%-14% oral olanzapine vs. 15% placebo; study 3:
7% oral olanzapine vs. 8% placebo). However, incidence of
Parkinsonism in the haloperidol treatment groups was sig-
nificantly higher than in the therapeutic oral olanzapine
groups in both oral study 1 (42% vs. 12%–14%, p’s≤ .001)
and study 2 (53% vs. 14%–19%, p’s< .001). Akathisia
showed a similar pattern, with no significant differences be-
tween olanzapine LAI and placebo (1%–6% olanzapine LAI
vs. 6% placebo) or therapeutic oral olanzapine and placebo
Table 3 Effect sizes for olanzapine oral or long-acting injection vs. placebo or non-therapeutic olanzapine (1 mg)

















405 mg/4 weeks olanzapine LAI 100 14.5 −22.5 .75 (moderate) −14.2 .71 (moderate)
210 mg/2 weeks olanzapine LAI 106 15.0 −22.8 .80 (large) −14.4 .77 (moderate)
300 mg/2 weeks olanzapine LAI 100 21.4 −24.8 .88 (large) −15.4 .82 (large)
vs. Placebo 98 0.0 −8.7 – −6.1 –
Oral Study 1
5 ± 2.5 mg/day olanzapine 65 6.6 – – −6.4 .17 (small)
10 ± 2.5 mg/day olanzapine 64 11.6 – – −12.2 .50 (moderate)
15 ± 2.5 mg/day olanzapine 69 16.3 – – −15.2 .67 (moderate)
15 ± 5.0 mg/day haloperidol 69 16.4 – – −12.8 .57 (moderate)
vs. Placebo 68 0.0 – – −3.7 –
Oral Study 2
5 ± 2.5 mg/day olanzapine 87 6.7 −21.4 .17 (small) −13.4 .19 (small)
10 ± 2.5 mg/day olanzapine 86 11.3 −22.7 .20 (small) −13.8 .19 (small)
15 ± 2.5 mg/day olanzapine 89 16.4 −26.7 .37 (moderate) −16.4 .38 (moderate)
15 ± 5.0 mg/day haloperidol 81 17.6 −20.0 .12 (small) −12.4 .12 (small)
vs. 1.0 mg/day olanzapine 88 0.0 −16.8 – −10.5 –
Oral Study 3
10 mg/day olanzapine (vs. placebo) 50 10.0 −12.3 .71 (moderate) −7.7 .60 (moderate)
10 mg/day olanzapine (vs. 1 mg) 50 10.0 −12.3 .48 (moderate) −7.7 .45 (moderate)
1 mg/day olanzapine (vs. placebo) 52 1.0 −1.9 .22 (moderate) −2.0 .14 (small)
Placebo 50 0.0 2.8 – −0.2 –
a All effect sizes were calculated from baseline-to-endpoint LOCF mean change scores at 6 weeks of treatment (OLZ LAI study was 8 weeks, whereas the 3 oral
studies were only 6 weeks)
b Effect sizes were categorized using Cohen’s general effect size thresholds [19]
Abbreviations: BPRS: Brief Psychiatric Rating Scale; LOCF: last observation carried forward; LS: least squares; OLZ LAI: olanzapine long-acting injection; PANSS:
Positive and Negative Syndrome Scale
Detke et al. BMC Psychiatry 2012, 12:51 Page 6 of 10
http://www.biomedcentral.com/1471-244X/12/51(study 1: 16%-27% oral olanzapine vs. 23% placebo; study 3:
13% oral olanzapine vs. 13% placebo). However, incidence
of akathisia in the haloperidol groups was significantly
higher than in the therapeutic oral olanzapine groups in
both oral study 1 (46% vs. 16%–27%, p’s< .05) and study 2
(34% vs. 9%–12%, p’s< .01).Discontinuation rates
In Table 5, results from all therapeutically dosed olanza-
pine treatment groups were combined within each of
the 4 studies to provide an overall rate of discontinu-
ation compared with the placebo group and the non-
therapeutic dose of oral olanzapine (1 mg/day) used in
oral studies 2 and 3. The rate of discontinuations from
any cause was lower in the olanzapine LAI study (com-
bined dosages of olanzapine LAI) compared with pla-
cebo and was also lower than the rates seen in oral
olanzapine studies 1 and 2 (combined dosages of oral
olanzapine, haloperidol, placebo, and non-therapeuticdose of oral olanzapine) and in oral olanzapine study 3
(oral olanzapine 10 mg/day, non-therapeutic dose of oral
olanzapine, and placebo). The rate of discontinuation
due to adverse events among patients treated with olan-
zapine LAI was comparable to patients in the placebo
group. Differences in overall discontinuation rate across
studies appeared to be driven primarily by higher rates
of discontinuation due to lack of efficacy in the oral
olanzapine studies 1 and 3 relative to the olanzapine
LAI study. The incidence of discontinuation due to an
adverse event for oral olanzapine in study 2 (11%) was
more than twice that of olanzapine LAI (4%), but no
statistical comparisons were made between the studies
regarding discontinuation rates.Discussion
This cross-study, post-hoc analysis indicates that
patients with acutely exacerbated schizophrenia treated
with olanzapine LAI dosages of 405 mg/4 weeks,
Table 5 Discontinuation rates for the olanzapine long-acting













All Causeb 42.9 31.0 67.6 56.5 56.1
Lack of Efficacy 24.5 11.4 47.1 27.5 32.3
Patient Decision 9.2 11.8 2.9 10.1 10.6
Adverse Event 5.1 4.2 10.3 8.7 5.1
Lost at Follow-
up
1.0 0.7 1.5 7.2 3.0
a Therapeutic dose groups were pooled
b All-cause percentages also include discontinuations for reasons other than those
Abbreviations: 1 mg: 1 mg/day non-therapeutic dose of olanzapine; HAL: haloperido
Table 4 Olanzapine plasma concentrations at study
endpoint for the olanzapine long-acting injection and
olanzapine oral studies







39 13.4 7.8 5.9 56.0
210 mg/2 weeks
olanzapine LAI
55 18.3 9.4 5.5 44.7
300 mg/2 weeks
olanzapine LAI
56 24.3 11.6 9.3 87.6
Oral Study 1
5 ± 2.5 mg/day
olanzapine
63 10.3 8.0 0.4 36.9
10 ± 2.5 mg/day
olanzapine
62 18.4 12.1 0.4 63.2
15 ± 2.5 mg/day
olanzapine




75 1.7 1.9 0.3 16.0
5 ± 2.5 mg/day
olanzapine
78 9.1 5.9 0.5 37.0
10 ± 2.5 mg/day
olanzapine
76 16.8 11.5 0.3 64.3
15 ± 2.5 mg/day
olanzapine




51 1.5 0.8 0.0 3.2
10 mg/day
olanzapine
48 20.7 17.1 0.3 93.0
Abbreviations: n: number of patients with evaluable samples; OLZ LAI:
olanzapine long-acting injection; SD: standard deviation
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magnitude of symptom reduction as patients treated
with 10 ± 2.5 mg/day and 15 ± 2.5 mg/day of oral olanza-
pine and 15 ± 5 mg/day of oral haloperidol during
6 weeks of acute treatment. Using historical clinical data
for oral olanzapine provided a helpful framework for
understanding the relative efficacy and tolerability of the
long-acting formulation of olanzapine.
Effect sizes
Importantly, the 4 studies presented in this analysis were
not conducted concurrently, and cross-study comparisons
should be interpreted with caution. Therefore, effect size
calculations were performed to allow a standardized com-
parison among the 4 studies. In general, an effect size above
0.5 standard deviations is considered “large” [19]. Compari-
son of effect sizes among the 4 studies suggests that the
magnitude of symptom reduction seen with the 3 doses of
olanzapine LAI was “large” and generally similar to that of
approximately 10 to 15 mg/day oral olanzapine or 15 mg/
day oral haloperidol. The evaluation of assessment scores
and relative effect sizes in this analysis demonstrate that
despite clinical and research changes over the years, the re-
sponse to treatment with olanzapine LAI as measured
against placebo was comparable to results from earlier oral
olanzapine clinical trials against placebo.
Onset of efficacy
The post-hoc exploration of early onset of action based on
mean change in symptoms measured by the BPRS or
PANSS total scales in each study suggests that speed of
onset with olanzapine LAI may be at least as rapid as that
of therapeutic doses of oral olanzapine and oral haloperi-
dol. Patients in all 3 treatment groups in the olanzapine
LAI study achieved statistically significant reduction in
symptoms within 1 week of receiving their first injection,
which was comparable to or better than results observed
for oral olanzapine in studies 1, 2, and 3. Of note in theinjection and olanzapine oral studies














44.3 46.9 37.8 80.0 76.9 62.0
18.2 19.8 14.1 74.0 61.5 56.0
9.1 7.4 7.3 5.8 2.0 2.0
11.4 14.8 10.7 0.0 9.6 4.0
1.1 2.5 1.5 4.0 0.0 0.0
shown
l; OLZ: olanzapine; LAI: long-acting injection; PLC: placebo
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allow supplementation with any oral antipsychotic medica-
tion, including oral olanzapine. The ability to begin to
realize improvement of acute symptoms following the first
injection, without the need for additional oral antipsychotic
medication for symptom control during the initial weeks
or months of treatment, may simplify the treatment plans
for patients with acute symptoms.
Olanzapine plasma concentrations
Pharmacokinetic evaluation indicated that olanzapine
plasma concentrations were in the therapeutic range as
early as day 3 for the LAI study. Moreover, endpoint con-
centrations were generally similar across the 4 studies.
These findings are consistent with the clinical observa-
tions. Interestingly, while all LAI patients had endpoint
concentrations within the therapeutic range, some oral
patients had concentrations below that range, suggesting
that some oral patients may have failed to take their dose.
Safety and tolerability
Weight gain is very commonly reported during treatment
with some atypical antipsychotics such as olanzapine. In
this analysis weight gain was most similar between olanza-
pine LAI and oral olanzapine in oral study 1, with patients
gaining a mean of 3.5 to 4 kg on the higher doses of olan-
zapine. Patients treated with olanzapine LAI or therapeutic
doses of oral olanzapine gained significantly more weight
than did those treated with haloperidol or placebo. A sig-
nificantly greater percentage of patients treated with olan-
zapine LAI or therapeutic doses of oral olanzapine gained
clinically significant amounts of weight than did those trea-
ted with haloperidol or placebo. Although these were all
short-term studies, it is important to note that changes in
metabolic parameters have also been reported during long-
term treatment with olanzapine [21,22]. Therefore, the po-
tential consequences of weight gain should be considered
prior to starting olanzapine treatment. Patients receiving
olanzapine should have their weight monitored regularly.
With respect to the development of extrapyramidal
symptoms, a significantly greater percentage of patients
treated with haloperidol experienced treatment-emergent
Parkinsonism or akathisia compared with those treated
with olanzapine LAI, oral olanzapine, or placebo. The
observed differences between the olanzapine LAI study
and the oral studies may be due in part to historical con-
text. At the time that the oral studies were conducted,
patients were more likely to have been treated with typical
antipsychotics previously, which may have influenced rates
of extrapyramidal symptoms in the study despite the
washout period. Also, rater expectations regarding extra-
pyramidal symptoms may have been different at that time,
and inclusion of a haloperidol arm may have also biased
rater expectations regarding extrapyramidal symptoms.Post-injection delirium/sedation syndrome (PDSS)
Although no cases of PDSS occurred during the acute
olanzapine LAI study, it is important to note that this is a
risk for this depot formulation. During other olanzapine
LAI clinical trials, adverse events related to delirium and/
or excessive sedation (including coma) were identified in a
small percentage of patients following injection. These
events have been reported following <0.1% of injections of
olanzapine LAI in <2% of patients [23]. Because of the risk
of PDSS, safety precautions—including a post-injection ob-
servation period— must occur at the time of each injec-
tion. Clinicians should consider these factors when
weighing the overall risks and benefits of olanzapine LAI
for each patient.
Study discontinuation rates
The low discontinuation rates in the olanzapine LAI study
are encouraging considering that discontinuation rates are
high in clinical studies of treatments for schizophrenia, but
it is important to recognize that discontinuation rates in
actual clinical use remain to be determined. Patients who
have difficulty adhering to medication schedules are usually
not participants in controlled clinical studies [24-26]. Add-
itionally, these studies employed both inpatient and out-
patient treatment settings which may have influenced the
overall study discontinuation rates. Nevertheless, the
present findings suggest possible improvement in treat-
ment persistence for patients who receive a long-acting
injection.
Limitations
These findings are based on 4 separate studies, each ana-
lyzed separately, with a span of approximately 10 years be-
tween the oral olanzapine studies and the olanzapine LAI
study. While effect size calculations help assess the magni-
tude of efficacy changes and comparison across baselines
show similarities of symptoms, there are differences that
must be considered when evaluating this information. Pa-
tient populations in these studies may have been different,
particularly in their previous exposure to medications.
Treatment paradigms at the time of the oral studies in the
early 1990s were based on the use of first generation anti-
psychotic medications while current treatment includes
the frequent use of second generation antipsychotic agents.
It should also be noted that although the present analyses
did not exclude any studies meeting our selection criteria,
all studies were conducted by Lilly and did not include
studies conducted by other sponsors.
It should also be noted that the present analyses are lim-
ited in their ability to provide comparisons of specific doses
between oral and olanzapine LAI because of the differing
length of time needed to reach steady state plasma concen-
trations for each olanzapine formulation. Olanzapine LAI
does not reach steady-state concentrations of olanzapine
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http://www.biomedcentral.com/1471-244X/12/51for at least 3 months, while oral olanzapine should reach
steady state levels within the first week of exposure. There-
fore, the LAI results seen in the 6-week period examined
in this work represent pre-steady state olanzapine levels,
which are slightly lower than the levels which will ultim-
ately be achieved over a longer period of time. For instance,
while the 405 mg/4 week dose may ultimately correspond
to a 15 mg/day oral dose, the short-term results presented
here indicate that this dose may provide olanzapine con-
centrations more similar to a 10 mg/day dose in the first
8 weeks of treatment. This is consistent with the pharma-
cokinetic and clinical findings from a previous study [27].
An additional consideration is that oral olanzapine studies
1 and 2 allowed semi-flexible dosing of the olanzapine tar-
get dose by ±2.5 mg/day while the olanzapine LAI study
used strictly fixed doses and prohibited any oral anti-
psychotic supplementation.
An additional limitation is that only 2 of the 3 oral stud-
ies were placebo-controlled, and the 1-mg oral olanzapine
reference dose did not perform like placebo with respect
to safety measures and some small differences in treat-
ment response. Therefore effect sizes vs. the 1-mg arm are
not comparable with effect sizes vs. placebo.
Conclusions
Patients treated acutely with olanzapine LAI showed a
similar pattern of improvement to that seen historically
in 3 previous studies of oral olanzapine. Onset of action
for the LAI formulation appeared as early as the first
week after injection, with olanzapine plasma concentra-
tions appearing similar across the LAI and oral studies.
With the exception of injection-related adverse events,
the efficacy and tolerability profile of olanzapine LAI is
similar to oral olanzapine.
Additional file
Additional file 1: Mean changes in PANSS total scores during six
weeks of treatment in olanzapine long-acting injection and oral
olanzapine studies of acute schizophrenia. This file contains a figure
depicting the visitwise mean changes in PANSS total scores for the 3
studies.
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